Leica Biosystems and Synthon Biopharmaceuticals have partnered to develop a companion diagnostic program for targeted cancer therapies. Leica will develop a fully automated tissue-based companion diagnostic test to run on its BOND™ automated advanced staining systems paired with one of Synthon’s antibody-drug conjugates, to enhance the treatment of solid tumors.

In December 2012, Leica Biosystems teamed up with Galena Biopharma to develop a companion diagnostic for Galena’s NeuVax™ (nelipepimut-S or E75) breast cancer therapeutic. Leica’s Bond Oracle™ Human Epidermal Growth Factor Receptor 2 (HER2) IHC System companion diagnostic was used to support the selection of the patients for the NeuVax Phase III PRESENT study.

Previous articleCatalent Raises China Stakes with Two Deals
Next articleAstellas and Ambit End Leukemia Drug Partnership